Profile: Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

25.83USD
4:00pm EDT
Price Change (% chg)

$2.42 (+10.34%)
Prev Close
$23.41
Open
$23.59
Day's High
$26.21
Day's Low
$23.59
Volume
566,142
Avg. Vol
312,570
52-wk High
$26.21
52-wk Low
$15.43

Search Stocks

Incyte Corporation (Incyte), incorporated in 1991, is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases.

JAKAFI

In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States. JAKAFI is distributed through a network of specialty pharmacy providers that work with IncyteCARES. The JAK family consists of four tyrosine kinases: JAK1, JAK2, JAK3 and Tyk2, is dysregulated in many oncologic and inflammatory conditions. JAKs are central to a number of biologic processes, including the formation and development of blood cells and the regulation of immune functions. LY3009104 is also being developed in psoriasis. Psoriasis is a skin disease that causes visible scaling and inflammation. In December 2011, Lilly initiated a Phase IIb double-blind, placebo-controlled, dose-ranging trial designed to evaluate LY3009104 in patients with moderate-to-severe plaque psoriasis.

c-MET for Solid Tumors

Incyte’s c-MET inhibitor, INCB28060, is licensed to Novartis. c-MET is a clinically validated receptor kinase cancer target. Dysregulation of the c-MET pathway triggers tumor growth, formation of new blood vessels that supply the tumor with nutrients, and causes cancer to spread to other organs. Dysregulation of the c-MET pathway is seen in many types of cancers, including kidney, liver, stomach, breast and brain.

IDO for Solid Tumors

The enzyme, indoleamine 2, 3-dioxygenase, IDO, is a key regulator of the mechanisms that are responsible for allowing tumors to escape from a patient's immune surveillance. Its compound, INCB24360, represents a inhibitor of the enzyme IDO.

Company Address

Incyte Corp

Experimetal Station
Route 141 & Henry Clay Rd.
Building E336
WILMINGTON   DE   19880
P: +1302.4986700
F: +1302.6365454

Search Stocks